A First-in-human, Open-label, Multiple Center Phase 1 Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetic, Immunogenicity, and Preliminary Efficacy of F182112 in Patients With Relapsed or Refractory Multiple Myeloma.
Latest Information Update: 04 Jan 2024
At a glance
- Drugs F 182112 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors Shandong New Time Pharmaceutical Co LTD
Most Recent Events
- 12 Dec 2023 Results (n=22) assessing the safety and efficacy of F182112 in patients with relapsed/refractory multiple myeloma, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 06 Jun 2023 Results (n=16; As of Feb 2,2023) assessing the efficacy and safety of F182112 in patients with relapsed/refractory multiple myeloma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 04 Aug 2021 New trial record